| ★ | SYNCHRONIZE-1: Survodutide Achieves Significant Weight Loss Versus Placebo | | 174 | Estados Unidos | |
| 7 | ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD | | 60.1K | Estados Unidos | 67 |
| 14 | Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D | | 1.6K | Estados Unidos | 66 |
| 19 | Inside the VESPER-3 Results: Berobenatide's Weight Loss Potential | | 839 | Estados Unidos | 65 |
| 3 | Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment | | 374 | Estados Unidos | 69 |
| 20 | Berobenatide Monthly GLP-1 Injectable Shows Promise for Weight Loss | | 250 | Estados Unidos | 65 |
| 6 | Hair Loss Update 2026: JAK Inhibitors, Oral Minoxidil, and Sequencing | | 209 | Estados Unidos | 67 |
| 16 | Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD | | 196 | Estados Unidos | 65 |
| 8 | Total Plaque Volume Indicates Patients With 0 CAC May Still be at Risk | | 120 | Estados Unidos | 67 |
| 17 | Brensocatib, 1 Year Later: Who Benefits Most? | Mark Metersky, MD | | 98 | Estados Unidos | 65 |
| 5 | Avapritinib's 4-Year Impact on Quality of Life in ISM | Thanai Pongdee, MD | | 73 | Estados Unidos | 68 |
| 18 | Recent Advancements and Ongoing Roadblocks in Cardiovascular Care for Women | | 65 | Estados Unidos | 65 |
| 1 | Addressing Advances and Roadblocks in Lipid Management, With Joseph Saseen, PharmD | | 64 | Estados Unidos | 76 |
| 4 | How Well-Being in Psoriasis is Being Assessed Via WHO-5, With Ulrich Mrowietz, MD | | 56 | Estados Unidos | 69 |
| 15 | AI-CPA Plaque Assessment Results Consistent, Reproducible Among Observers | | 41 | Estados Unidos | 66 |
| 2 | FMD Peak Systolic Velocity May Lead to Comprehensive Clinical Guidelines | | 33 | Estados Unidos | 70 |
| 9 | Diagnosing Non-IgE Food Hypersensitivity | Brian Lacy, MD, PhD | EAC 2026 | | 31 | Estados Unidos | 67 |
| 11 | Addressing the Manifold Barriers in Hypertension, With Michael Miedema, MD | | 27 | Estados Unidos | 67 |
| 12 | Brief, Regular Movement Breaks Can Improve Cardiovascular Risk in T2D | | 24 | Estados Unidos | 67 |
| 13 | How ABCG2 Inhibition Could Change EPP Disease Management | | 17 | Estados Unidos | 66 |
| 10 | What's Next for Peanut Allergy Microneedle Immunotherapy, With Brian Vickery, MD | | 12 | Estados Unidos | 67 |